GASC
MCID: GST053
MIFTS: 83

Gastric Cancer (GASC)

Categories: Blood diseases, Cancer diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Gastric Cancer

MalaCards integrated aliases for Gastric Cancer:

Name: Gastric Cancer 57 11 19 73 28 53 5 33
Stomach Cancer 11 19 75 73 41 14 33
Gastric Carcinoma 11 53 16 75 33
Stomach Carcinoma 11 19 14 71
Malignant Neoplasm of Stomach 71 31
Gastric Cancer, Somatic 57 12
Carcinoma of Stomach 11 33
Stomach Neoplasms 43 71
Gastric Neoplasm 11 5
Gastric Cancer Risk After H. Pylori Infection 57
Primary Malignant Neoplasm of Body of Stomach 33
Primary Malignant Neoplasm of Pyloric Antrum 33
Malignant Tumor of Lesser Curve of Stomach 71
Malignant Neoplasm of Body of Stomach 71
Gastrocarcinoma of Unspecified Site 33
Carcinoma of Fundus of Stomach 33
Cancer of Fundus of Stomach 33
Malignant Tumour of Stomach 33
Cancer of Body of Stomach 33
Gastric Cancer Intestinal 73
Adult Stomach Carcinoma 19
Leather Bottle Stomach 33
Pyloric Antrum Cancer 33
Cancer of the Stomach 11
Adult Stomach Cancer 19
Gastric Carcinomas 14
Stomach Neoplasm 16
Gastric Cancers 14
Cancer, Gastric 38
Gasc 73

Classifications:



External Ids:

Disease Ontology 11 DOID:10534 DOID:5517
OMIM® 57 613659
MeSH 43 D013274
SNOMED-CT via HPO 69 372143007
UMLS 71 C0024623 C0038356 C0153421 more

Summaries for Gastric Cancer

GARD: 19 "Stomach cancer, also called gastric cancer, is a form of cancer that occurs due to abnormal and uncontrolled cell growth in the stomach. Most people with early Stomach cancer have no signs or symptoms of the condition. In advanced stages, symptoms may include indigestion; nausea and vomiting; difficulty swallowing; feeling full after eating small amounts of food; loss of appetite; vomiting blood; fatigue; and/or weight loss. Most cases of Stomach cancer occur sporadically in people with little to no family history of the condition; however, approximately 10% of Stomach cancers are considered ""familial."" Although the underlying cause of some familial cases is unknown, genetic changes are identified in a subset of people affected by Stomach cancer. Hereditary cancer syndromes associated with a predisposition to Stomach cancer include hereditary diffuse gastric cancer, Lynch syndrome, Li-Fraumeni syndrome, familial adenomatous polyposis, and Peutz-Jeghers syndrome. In other families, a cluster of Stomach cancers may be due to a combination of gene(s) and/or other shared factors such as environment and lifestyle."

MalaCards based summary: Gastric Cancer, also known as stomach cancer, is related to diffuse gastric and lobular breast cancer syndrome and diffuse gastric cancer, and has symptoms including abdominal pain, constipation and diarrhea. An important gene associated with Gastric Cancer is APC (APC Regulator Of WNT Signaling Pathway), and among its related pathways/superpathways are Prolactin Signaling and Overview of interferons-mediated signaling pathway. The drugs Thalidomide and Iron isomaltoside 1000 have been mentioned in the context of this disorder. Affiliated tissues include stomach, lymph node and small intestine, and related phenotypes are stomach cancer and increased level of l-fucose in urine

MedlinePlus: 41 The stomach is an organ between the esophagus and the small intestine. It mixes food with stomach acid and helps digest protein. Stomach cancer mostly affects older people - two-thirds of people who have it are over age 65. Your risk of getting it is also higher if you: Have had a Helicobacter pylori infection Have had stomach inflammation Are a man Eat lots of salted, smoked, or pickled foods Smoke cigarettes Have a family history of stomach cancer It is hard to diagnose stomach cancer in its early stages. Indigestion and stomach discomfort can be symptoms of early cancer, but other problems can cause the same symptoms. In advanced cases, there may be blood in your stool, vomiting, unexplained weight loss, jaundice, or trouble swallowing. Doctors diagnose stomach cancer with a physical exam, blood and imaging tests, an endoscopy, and a biopsy. Because it is often found late, it can be hard to treat stomach cancer. Treatment options include surgery, chemotherapy, radiation or a combination. NIH: National Cancer Institute

UniProtKB/Swiss-Prot: 73 A malignant disease which starts in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. The term gastric cancer or gastric carcinoma refers to adenocarcinoma of the stomach that accounts for most of all gastric malignant tumors. Two main histologic types are recognized, diffuse type and intestinal type carcinomas. Diffuse tumors are poorly differentiated infiltrating lesions, resulting in thickening of the stomach. In contrast, intestinal tumors are usually exophytic, often ulcerating, and associated with intestinal metaplasia of the stomach, most often observed in sporadic disease.

OMIM®: 57 In a review article on the genetic predisposition to gastric cancer, Bevan and Houlston (1999) concluded that several genes may be associated with an increased risk of gastric cancer. Gastric cancer is a manifestation of a number of inherited cancer predisposition syndromes, including hereditary nonpolyposis colon cancer (HNPCC1; see 120435), familial adenomatous polyposis (FAP; 175100), Peutz-Jeghers syndrome (PJS; 175200), Cowden disease (CD; 158350), the Li-Fraumeni syndrome (151623), and diffuse gastric and lobular breast cancer syndrome (DGLBC; 137215). Canedo et al. (2007) provided a review of genetic susceptibility to gastric cancer in patients infected with Helicobacter pylori (see 600263). (613659) (Updated 24-Oct-2022)

Disease Ontology 11 Stomach cancer: A gastrointestinal system cancer that is located in the stomach.

Stomach carcinoma: A stomach cancer that is located in the stomach.

Wikipedia: 75 Stomach cancer, also known as gastric cancer, is a cancer that develops from the lining of the stomach.... more...

Related Diseases for Gastric Cancer

Diseases in the Gastric Cancer family:

Hereditary Gastric Cancer

Diseases related to Gastric Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1753)
# Related Disease Score Top Affiliating Genes
1 diffuse gastric and lobular breast cancer syndrome 34.4 PIK3CA MUTYH KRAS ERBB2 BRCA2
2 diffuse gastric cancer 33.9 MUTYH KRAS ERBB2 BRCA2
3 colorectal cancer 33.8 PIK3CA MUTYH MIR27A MIR25 MIR221 MIR215
4 gastric adenocarcinoma 33.7 PIK3CA KRAS FGFR2 ERBB2 APC
5 esophageal cancer 33.4 PIK3CA MIR27A MIR221 MIR21 MIR145 MIR143
6 adenocarcinoma 33.1 PIK3CA KRAS FGFR2 ERBB2 BRCA2 APC
7 breast cancer 33.1 PIK3CA MUTYH MIR27A MIR221 MIR21 MIR145
8 hepatocellular carcinoma 33.0 PIK3CA MIR27A MIR25 MIR221 MIR215 MIR21
9 lung cancer 33.0 PIK3CA MIR27A MIR25 MIR221 MIR21 MIR15B
10 small intestine cancer 32.9 PIK3CA MUTYH KRAS ERBB2
11 colonic benign neoplasm 32.9 PIK3CA MUTYH MIR21 MIR145 MIR143 KRAS
12 lung cancer susceptibility 3 32.7 PIK3CA MIR27A MIR25 MIR21 MIR145 MIR143
13 pancreatic cancer 32.7 PIK3CA MIR25 MIR221 MIR21 MIR15B MIR145
14 ovarian cancer 32.7 PIK3CA MUTYH MIR27A MIR221 MIR21 MIR145
15 gastrointestinal system disease 32.7 MIR27A MIR25 MIR221 MIR215 MIR21 MIR15B
16 stomach disease 32.7 MIR27A MIR25 MIR221 MIR215 MIR21 MIR15B
17 peripheral nervous system disease 32.6 MIR27A MIR21 MIR145 MIR143 KRAS IL1B
18 lynch syndrome 32.5 PIK3CA MUTYH KRAS FGFR2 ERBB2 BRCA2
19 adenoma 32.4 PIK3CA MUTYH KRAS APC
20 head and neck cancer 32.4 PIK3CA MIR27A MIR25 MIR221 MIR21 MIR145
21 prostate cancer 32.3 PIK3CA MIR27A MIR25 MIR221 MIR21 MIR145
22 esophagus adenocarcinoma 32.3 MIR215 MIR21 MIR145 MIR143 ERBB2
23 type 2 diabetes mellitus 32.3 PIK3CA MIR27A MIR221 MIR21 MIR15B MIR145
24 rectum cancer 32.3 MUTYH MIR221 MIR215 MIR21 MIR145 MIR143
25 leukemia, acute myeloid 32.3 PIK3CA MIR27A MIR25 MIR221 MIR21 MIR15B
26 leukemia, chronic lymphocytic 32.2 MIR27A MIR221 MIR21 MIR15B MIR145 MIR143
27 renal cell carcinoma, nonpapillary 32.2 PIK3CA MIR27A MIR25 MIR221 MIR21 MIR145
28 gastrointestinal system cancer 32.2 MIR27A MIR25 MIR221 MIR215 MIR21 MIR15B
29 bladder cancer 32.2 PIK3CA MIR221 MIR21 MIR145 MIR143 KRAS
30 endometrial cancer 32.2 PIK3CA MUTYH MIR21 MIR145 KRAS FGFR2
31 papillary adenocarcinoma 32.1 MIR221 MIR21 KRAS ERBB2
32 gastrointestinal stromal tumor 32.1 PIK3CA KRAS FGFR2 ERBB2
33 mucinous adenocarcinoma 32.0 PIK3CA KRAS ERBB2
34 brain cancer 32.0 PIK3CA MIR25 MIR221 MIR21 MIR145 MIR143
35 cervical cancer 32.0 PIK3CA MIR27A MIR25 MIR221 MIR21 MIR143
36 intestinal benign neoplasm 31.9 PIK3CA MUTYH MIR21 MIR143 KRAS IL1B
37 rectal benign neoplasm 31.9 PIK3CA MIR145 MIR143 KRAS
38 hematologic cancer 31.9 MIR27A MIR25 MIR221 MIR21 MIR15B MIR145
39 skin disease 31.9 PIK3CA MIR27A MIR25 MIR221 MIR21 KRAS
40 gastroesophageal adenocarcinoma 31.9 PIK3CA KRAS FGFR2 ERBB2
41 cholangiocarcinoma 31.9 PIK3CA MIR21 KRAS FGFR2 ERBB2 BRCA2
42 lymphoma, non-hodgkin, familial 31.9 PIK3CA MIR27A MIR21 MIR15B MIR145 MIR143
43 exanthem 31.9 KRAS IL1B ERBB2
44 cerebrovascular disease 31.9 MIR27A MIR221 MIR21 MIR145 MIR143 IL1B
45 myeloma, multiple 31.8 PIK3CA MIR27A MIR25 MIR221 MIR21 MIR145
46 connective tissue disease 31.8 MIR27A MIR25 MIR221 MIR21 MIR15B MIR145
47 bile duct cancer 31.8 PIK3CA MIR221 MIR21 MIR145 MIR143 KRAS
48 lymphatic system disease 31.8 MIR27A MIR25 MIR221 MIR21 MIR15B MIR145
49 kidney cancer 31.8 PIK3CA MIR27A MIR221 MIR21 MIR145
50 li-fraumeni syndrome 31.8 PIK3CA MUTYH KRAS ERBB2 BRCA2

Comorbidity relations with Gastric Cancer via Phenotypic Disease Network (PDN): (show all 11)


Active Peptic Ulcer Disease Acute Cystitis
Deficiency Anemia Gastric Fundus Cancer
Heart Disease Intestinal Obstruction
Iron Deficiency Anemia Neutropenia
Protein-Energy Malnutrition Pylorus Cancer
Stomach Carcinoma in Situ

Graphical network of the top 20 diseases related to Gastric Cancer:



Diseases related to Gastric Cancer

Symptoms & Phenotypes for Gastric Cancer

Human phenotypes related to Gastric Cancer:

30
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 stomach cancer 30 HP:0012126
2 increased level of l-fucose in urine 30 HP:0410067

Clinical features from OMIM®:

613659 (Updated 24-Oct-2022)

UMLS symptoms related to Gastric Cancer:


abdominal pain; constipation; diarrhea; dyspepsia; heartburn; icterus; nausea and vomiting; gastrointestinal gas

MGI Mouse Phenotypes related to Gastric Cancer:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.81 APC BRCA2 ERBB2 FGFR2 IL1B IRF1
2 cardiovascular system MP:0005385 9.7 APC ERBB2 FGFR2 IL1B IL1RN IRF1
3 integument MP:0010771 9.32 APC BRCA2 ERBB2 FGFR2 IL1B IL1RN

Drugs & Therapeutics for Gastric Cancer

Drugs for Gastric Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 565)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Thalidomide Approved, Investigational, Withdrawn Phase 4 50-35-1 5426
2
Iron isomaltoside 1000 Approved, Investigational Phase 4 1370654-58-2
3
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
4
Pravastatin Approved Phase 4 81093-37-0 54687
5
Magnesium sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9
6
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
7
Dexmedetomidine Approved, Experimental, Vet_approved Phase 4 86347-14-0, 113775-47-6 68602 5311068
8
Simethicone Approved Phase 4 8050-81-5
9
Acetylcysteine Approved, Investigational Phase 4 616-91-1 581 12035
10
Nicotine Approved Phase 4 54-11-5 942 89594
11
Morphine Approved, Investigational Phase 4 57-27-2 5288826
12
Bupropion Approved Phase 4 31677-93-7, 34841-39-9, 34911-55-2 444
13
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
14
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
15
Potassium citrate Approved, Investigational, Vet_approved Phase 4 866-84-2
16
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
17
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
18
Lutetium Lu 177 dotatate Approved, Investigational Phase 4 437608-50-9 76966897
19
Droperidol Approved, Vet_approved Phase 4 548-73-2 3168
20
Metronidazole Approved Phase 4 443-48-1, 69198-10-3 4173
21
Clarithromycin Approved Phase 4 81103-11-9 84029
22
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6 9578005
23
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
24
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
25
Esomeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6, 119141-88-7 9568614 4594
26
Rabeprazole Approved, Investigational Phase 4 117976-89-3, 117976-90-6 5029
27
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
28
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
29
Ofloxacin Approved Phase 4 82419-36-1 4583
30
Pantoprazole Approved Phase 4 102625-70-7, 138786-67-1 4679
31
Iron Approved Phase 4 7439-89-6 29936
32
L-Glutamine Approved, Investigational, Nutraceutical Phase 4 56-85-9 5961
33
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
34
D-Lysine Approved, Experimental, Nutraceutical Phase 4 923-27-3, 56-87-1 57449 5962
35
Doxifluridine Investigational Phase 4 3094-09-5 18343
36
Furazolidone Experimental, Vet_approved Phase 4 67-45-8 5323714
37 Omega 3 Fatty Acid Phase 4
38 Lipid Regulating Agents Phase 4
39 Anticholesteremic Agents Phase 4
40 Hypolipidemic Agents Phase 4
41 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
42 Coagulants Phase 4
43 Purinergic P2Y Receptor Antagonists Phase 4
44 Soybean oil, phospholipid emulsion Phase 4
45 Soy Bean Phase 4
46 Fat Emulsions, Intravenous Phase 4
47 Antidotes Phase 4
48 Protective Agents Phase 4
49 Antiviral Agents Phase 4
50 Anti-Infective Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 2362)
# Name Status NCT ID Phase Drugs
1 Phase IV Multi-Institutional Randomized Trial of Capecitabine Plus Oxaliplatin With Bevacizumab in Patients With Potentially Resectable Gastric Cancer With Liver Metastasis Unknown status NCT01962376 Phase 4 Oxaliplatin;Capecitabine;Oxaliplatin;Capecitabine;Bevacizumab
2 Community-based Helicobacter Pylori Eradication With Two Sequential Antibiotic Regimens for the Residents and Migrants From a High-risk Area for Gastric Cancer Unknown status NCT00155389 Phase 4 Helicobacter pylori eradication
3 Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients With Advanced Colorectal or Gastric Cancer Treated With FOLFIRI Regimen Unknown status NCT01271582 Phase 4 Irinotecan, 5FU, leucovorin
4 A Clinical Trial of Maintenance Treatment of Apatinib in Advanced Gastric Cancer Patients Have Completed Postoprative Adjuvant Chemotherapy Unknown status NCT02776527 Phase 4 Apatinib Mesylate Tablets
5 Efficacy of Perioperative Application of Omega-3 Polyunsaturated Fatty Acids on Postoperative Immunization in Gastric Cancer Patients - A Prospective, Randomized Clinical Trial Unknown status NCT01910948 Phase 4 omega-3 polyunsaturated fatty acids
6 Fast-track Surgery Recovery Program With Early Jejunostomy Nutrition Protocol Minimizes Time to Adjuvant Chemotherapy in Patients Undergoing Laparoscopic Gastrectomy for Gastric Cancer Unknown status NCT01766765 Phase 4
7 Phase IV Multi-Institutional Randomized Trial of Capecitabine Plus Oxaliplatin With Herceptin in Patients With Potentially Resectable HER-2 Positive Gastric Cancer With Liver Metastasis Unknown status NCT02380131 Phase 4 Oxaliplatin plus Capecitabine;Herceptin
8 Irinotecan Plus Thalidomide in Second Line Advanced Gastric Cancer : A Multicenter, Randomized, Controlled and Prospective Trial Unknown status NCT02401971 Phase 4 Thalidomide;CPT-11
9 H.O.P.E. Healing Optimization Through Preoperative Engagement: A Prospective Single Cohort Study to Evaluate the Effect of a Prehabilitation Program on Preoperative Outcomes in Upper GI Surgical Oncology Patients Unknown status NCT03642093 Phase 4
10 The Use of Fibrin Glue Sealant (Tisseel®) as a Reinforcement of Esophagojejunal Anastomoses Will Decrease the Rate of Anastomotic Leak. Unknown status NCT03733639 Phase 4 Tisseel
11 An Pilot Study to Assess the Efficacy of Intravenous Iron Isomaltoside 1000 (Monofer®) in the Management of Anaemia Associated With the Palliative Management of Oesophagogastric Adenocarcinoma Unknown status NCT01927328 Phase 4 Iron isomaltoside 1000
12 Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD? Unknown status NCT01621451 Phase 4 aspirin and/or clopidogrel
13 Randomized Controlled Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4 Pravastatin
14 Randomized Clinical Trial of Omega-3 Fatty Acid-supplemented Parenteral Nutrition Versus Standard Parenteral Nutrition in Patients Undergoing Major Laparoscopic Abdominal Surgery Unknown status NCT01819961 Phase 4 MCT/LCT and fish oil;MCT/LCT
15 ONCOXIN® and Quality of Life in Cancer Patients in a Real World Setting Study Completed NCT03550482 Phase 4
16 Effects of Ilaprazole 20mg on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone Endoscopic Submucosal Dissection(ESD) for Gastric Adenoma or Early Gastric Cancer. Completed NCT02638584 Phase 4 Ilaprazole;Rabeprazole
17 Application of Somatostatin for Advanced Gastric Cancer After D2 Lymph Node Dissection -a Prospective Randomized Controlled Study Completed NCT01914692 Phase 4 Somatostatin
18 Rescue Therapy for Helicobacter Pylori Eradication: A Randomized and Non-inferiority Trail of Berberine Plus Amoxicillin Quadruple Therapy Versus Tetracycline Plus Furazolidone Quadruple Therapy Completed NCT03609892 Phase 4 Berberine;Amoxicillin;Esomeprazole;Bismuth;Tetracycline;Furazolidone
19 Improving Complete Endoscopic Mucosal Resection (EMR) of Colorectal Neoplasia: A Randomized Prospective Comparison of Snares and Injectate in the Resection of Large Sessile Colonic Polyps Completed NCT01471756 Phase 4
20 Comparison of the Analgesic Effect Between Intrathecal Morphine and IV-fentanyl Patient Controlled Analgesia (ITM-IVPCA) and Epidural PCA (PCEA) in Patients Undergoing Gastrectomy -Randomized Allocation Study- Completed NCT01234272 Phase 4 morphine;Ropivacaine
21 Prospective Controlled Randomized Comparative Study About Quality of Life (QoL), Immunomodulation and Safety of Adjuvant Mistletoe Treatment in Patients With Gastric Carcinoma Receiving Chemotherapy After Operation Completed NCT01401075 Phase 4 mistletoe extract;doxifluridine
22 Standard and Immunostimulating Enteral Nutrition in Patients After Extended Gastrointestinal Surgery - A Prospective, Randomized, Controlled Clinical Trial Completed NCT00576940 Phase 4 Reconvan;Peptisorb
23 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
24 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
25 Comparison of Efficacy of Bismuth Potassium Citrate, Pectin Bismuth Capsules, and Pectin Bismuth Granules in the Treatment of Helicobacter Pylori (Hp) First-line Quadruple Regimen: a Multicenter, Randomized, Prospective, Comparative Clinical Trial Completed NCT04209933 Phase 4 Bismuth potassium citrate containing quadruple therapy;Colloidal pectin bismuth capsules containing quadruple therapy;Colloidal pectin bismuth particles A quadruple therapy;Colloidal pectin bismuth particles B quadruple therapy
26 The Effects of Intraoperative Dexmedetomidine Infusion on Postoperative Bowel Movement in Patients Undergoing Laparoscopic Gastrectomy Completed NCT02164448 Phase 4 the dexmedetomidine group;the control group
27 Randomised Trial of the Effects of Individual Nutritional Counseling in Cancer Patients Completed NCT01962272 Phase 4
28 Title: The Impact of Immunostimulating Nutrition on Infectious Complications After Upper Gastrointestinal Surgery - A Prospective, Randomized, Clinical Trial. Completed NCT00558155 Phase 4 peptisorb;Stresson;Parenteral nutrition;Omegaven, Dipeptiven
29 Comparison of the Effects of Continuous Epidural Analgesia and Continuous Intravenous Analgesia on Postoperative Bowel Movement in Patients Undergoing Laparoscopic Gastrectomy Completed NCT02458573 Phase 4
30 Whether 18F-ALF-NOTA-PRGD2 PET/CT Scan Can Predict the Efficacy and Adverse Events of Apatinib in Patients With Malignancies. Completed NCT03384511 Phase 4 Apatinib
31 Effectiveness of Premedication With Simethicone or Simethicone Plus N-acetylcysteine vs. Placebo in Improving Visibility During Upper Endoscopy. Completed NCT01653171 Phase 4 Water (Placebo);Simethicone;N-acetylcysteine 500 mg;N-acetylcysteine 1000 mg
32 A Randomized, Controlled, Double-blind Trial of the Efficacy and Safety of CO2 vs Room Air Insufflation During ESD for Gastric Tumor Completed NCT01579071 Phase 4
33 Effect of H. Pylori Eradication on the Fate of H. Pylori-associated Gastric Polyp (Randomized Controlled Study) Completed NCT03065868 Phase 4 H. pylori eradication (Amoxaxillin, Lanston, Clarithromycin)
34 The Effect of Perioperative Intravenous Magnesium on Pain After Endoscopic Submucosal Dissection for Gastric Neoplasm: Prospective Randomized Double-blind Placebo Controlled Study Completed NCT02235246 Phase 4 Magnesium Sulfate;Normal saline
35 PERIOP-FOLFIRINOX: A Pilot Trial of Perioperative Genotype-guided Irinotecan Dosing of gFOLFIRINOX for Locally Advanced Gastroesophageal Adenocarcinoma Recruiting NCT02366819 Phase 4 Oxaliplatin;Leucovorin Calcium;Irinotecan Hydrochloride;Fluorouracil
36 A Multi-center, Phase IV, Extension Study in PEGASUS-D Trial to Evaluate Efficacy of Ursodeoxycholic Acid (UDCA) for the Prevention of Gallstone Formation After Gastrectomy in Patients With Gastric Cancer Recruiting NCT05410535 Phase 4 Patients who continued UDCA 300mg medication
37 The Effect of Chemoradiotherapy on Gastric Perfusion in Patients With Gastric Cancer. Recruiting NCT05354856 Phase 4 Indocyanine green
38 Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer Mortality Recruiting NCT02047994 Phase 4 Triple therapy
39 The Effect of Postoperative Supplemental Parenteral Nutrition (SPN) in Gastric Cancer Patients Who Underwent Gastrectomy: A Multicenter Prospective Randomized Controlled Trial Recruiting NCT04607057 Phase 4 Parenteral Nutrition Solutions
40 The Incidences Of Hypoxia And Severe Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol Compared With Propofol In Overweight Or Obesity Adults Patients, A Multicenter, Randomized, Controlled Trial Recruiting NCT05518929 Phase 4 Ciprofol;Propofol
41 Low-dose Neuroleptanalgesia Reduce the Occurrences of Postoperative Delirium in Elderly Patients Undergoing Non-cardiac Major Surgery : a Randomized Controlled Trial Recruiting NCT05068180 Phase 4 low-dose neuroleptanalgesia;Placebo
42 A Multicenter, Open-label Post Authorization Safety Study to Evaluate the Effect of LysaKare® Infusion on Serum Potassium Levels in GEP-NET Patients Eligible for Lutathera® Treatment Recruiting NCT04524442 Phase 4 arginine/lysine
43 A Real World Study of Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication Enrolling by invitation NCT04660123 Phase 4 Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication
44 Efficacy and Safety of Berberine Hydrochloride, Amoxicillin and Rabeprazole Triple Therapy in the First Eradication of Helicobacter Pylori Enrolling by invitation NCT04697186 Phase 4 Berberine;Amoxicillin;Rabeprazole;Clarithromycin;Bismuth
45 Rescue Therapy for Helicobacter Pylori Eradication: A Randomized and Non-inferiority Trail of High-dose Esomeprazole and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy Enrolling by invitation NCT04678492 Phase 4 Esomeprazole;Amoxicillin;Bismuth;Tetracycline;Furazolidone
46 A Prospective, Multicenter, Randomized Controlled Study of Apatinib Combined With Chemotherapy Versus Chemotherapy in Second-line Gastric Cancer Receiving Prior Anti-PD-1 Therapy Not yet recruiting NCT05029453 Phase 4 Apatinib
47 Preoperative Intravenous Iron Therapy in Patients With Gastric Cancer Not yet recruiting NCT04168346 Phase 4 Ferric carboxymaltose;Placebos
48 Indocyanine Green Lymphangiography as a Tool for Improving Lymphadenectomy in Gastric Cancer Not yet recruiting NCT04591028 Phase 4 Indocyanine green
49 Yiqi Wenyang Jiedu Prescription in the Prevention and Treatment of Postoperative Metastasis and Recurrence of Gastric Cancer:A Randomized, Double-blind, Controlled and Multi-center Clinical Study Not yet recruiting NCT05229809 Phase 4 Yiqi Wenyang Jiedu prescription;Simulation agent of Yiqi Wenyang Jiedu prescription
50 An Open-label, Multicentre Phase IV Study of Trastuzumab in Combination With the Standard Therapy (as Per Routine Clinical Practice) as First-line Therapy in Patients With HER2 Positive Metastatic Gastric Cancer Terminated NCT01260194 Phase 4 trastuzumab [Herceptin]

Search NIH Clinical Center for Gastric Cancer

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cisplatin
CISPLATIN PWDR
docetaxel
Floxuridine
Fluorouracil
Ifosfamide
irinotecan
Irinotecan hydrochloride
Methotrexate
Methotrexate Sodium

Cochrane evidence based reviews: stomach neoplasms

Genetic Tests for Gastric Cancer

Genetic tests related to Gastric Cancer:

# Genetic test Affiliating Genes
1 Gastric Cancer 28 APC CASP10 ERBB2 FGFR2 IL1B IL1RN IRF1 KLF6 KRAS MUTYH PIK3CA

Anatomical Context for Gastric Cancer

Organs/tissues related to Gastric Cancer:

FMA: Stomach, Stomach
MalaCards : Lymph Node, Small Intestine, Liver, Breast, Colon, T Cells, Bone Marrow

Publications for Gastric Cancer

Articles related to Gastric Cancer:

(show top 50) (show all 52178)
# Title Authors PMID Year
1
Inactivating mutations of the caspase-10 gene in gastric cancer. 53 62 57 5
11973654 2002
2
Functionally inactivating point mutation in the tumor-suppressor IRF-1 gene identified in human gastric cancer. 53 62 57 5
9679752 1998
3
Genetic alterations of the MYH gene in gastric cancer. 53 57 5
15273732 2004
4
The APC gene, responsible for familial adenomatous polyposis, is mutated in human gastric cancer. 62 57 5
1317264 1992
5
Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. 53 62 57
18488030 2008
6
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. 53 62 5
15608678 2005
7
Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. 53 62 57
11419427 2001
8
Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. 53 62 5
11325814 2001
9
Analysis for microsatellite instability and mutations of the DNA mismatch repair gene hMLH1 in familial gastric cancer. 53 62 57
8938136 1996
10
Microsatellite instability and mutations of p53 and TGF-beta RII genes in gastric cancer. 53 62 57
8882883 1996
11
A novel genomic classification system of gastric cancer via integrating multidimensional genomic characteristics. 62 5
34095982 2021
12
Unraveling genetic predisposition to familial or early onset gastric cancer using germline whole-exome sequencing. 62 5
28875981 2017
13
Short rare MUC6 minisatellites-5 alleles influence susceptibility to gastric carcinoma by regulating gene. 62 57
20506113 2010
14
Biallelic MYH germline mutations as cause of Muir-Torre syndrome. 53 5
19998059 2010
15
miR-21 plays a pivotal role in gastric cancer pathogenesis and progression. 53 62 46
18794849 2008
16
E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. 53 62 46
18328430 2008
17
After Helicobacter pylori, genetic susceptibility to gastric carcinoma revisited. 62 57
17991176 2007
18
Genetic alterations of the KLF6 gene in gastric cancer. 62 57
15824733 2005
19
Gastric cancer originating from bone marrow-derived cells. 62 57
15567866 2004
20
A novel splice-site variant of the base excision repair gene MYH is associated with production of an aberrant mRNA transcript encoding a truncated MYH protein not localized in the nucleus. 53 5
15180946 2004
21
Genetic susceptibility and gastric cancer risk. 62 57
12115538 2002
22
Familial and second gastric carcinomas: a nationwide epidemiologic study from Sweden. 62 57
11920487 2002
23
Red meat, family history, and increased risk of gastric cancer with microsatellite instability. 62 57
11454685 2001
24
Interleukin-1 polymorphisms associated with increased risk of gastric cancer. 62 57
10746728 2000
25
Familial gastric cancer: overview and guidelines for management. 62 57
10593993 1999
26
Genetic predisposition to gastric cancer. 62 57
10209666 1999
27
Microsatellite instability in gastric cancer is associated with tumor location and family history in a high-risk population from Tuscany. 62 57
9377564 1997
28
Loss of heterozygosity of APC/MCC gene in differentiated and undifferentiated gastric carcinomas in Taiwan. 62 57
7585453 1995
29
Clinicopathologic significance of the K-ras gene codon 12 point mutation in stomach cancer. An analysis of 140 cases. 62 5
7773929 1995
30
Detection of 17p loss in gastric carcinoma using polymerase chain reaction. 62 57
7853854 1995
31
Family history and the risk of stomach and colorectal cancer. 62 57
1606546 1992
32
Familial occurrence of gastric cancer in the 2-year experience of a population-based registry. 62 57
2224804 1990
33
The decline in gastric cancer: epidemiology of an unplanned triumph. 62 57
3533579 1986
34
THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. 62 57
14320675 1965
35
Somatic PIK3CA Mutations in Sporadic Cerebral Cavernous Malformations. 5
34496175 2021
36
DUAL-ENERGY X-RAY ABSORPTIOMETRY AND CALCULATED FRAX RISK SCORES MAY UNDERESTIMATE OSTEOPOROTIC FRACTURE RISK IN VITAMIN D-DEFICIENT VETERANS WITH HIV INFECTION. 5
26684149 2016
37
Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. 5
26266985 2015
38
PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours. 5
26266975 2015
39
Identification of Medically Actionable Secondary Findings in the 1000 Genomes. 5
26332594 2015
40
Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 5
25157968 2014
41
Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. 5
24733792 2014
42
MUTYH-associated polyposis (MAP): evidence for the origin of the common European mutations p.Tyr179Cys and p.Gly396Asp by founder events. 5
23361220 2014
43
Germline variation in cancer-susceptibility genes in a healthy, ancestrally diverse cohort: implications for individual genome sequencing. 5
24728327 2014
44
Personalized genomic disease risk of volunteers. 5
24082139 2013
45
Loss of MUTYH function in human cells leads to accumulation of oxidative damage and genetic instability. 5
23108399 2013
46
Colorectal cancer in a monoallelic MYH mutation carrier. 5
23625202 2013
47
Oncogenic ERBB3 mutations in human cancers. 5
23680147 2013
48
Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly. 5
23100325 2013
49
Germline Mutations in the Polyposis-Associated Genes BMPR1A, SMAD4, PTEN, MUTYH and GREM1 Are Not Common in Individuals with Serrated Polyposis Syndrome. 5
23805267 2013
50
Cancer-associated variants and a common polymorphism of MUTYH exhibit reduced repair of oxidative DNA damage using a GFP-based assay in mammalian cells. 5
22926731 2012

Variations for Gastric Cancer

ClinVar genetic disease variations for Gastric Cancer:

5 (show top 50) (show all 98)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 CASP10 NM_032977.4(CASP10):c.769C>T (p.Gln257Ter) SNV Pathogenic
7766 rs121909775 GRCh37: 2:202070652-202070652
GRCh38: 2:201205929-201205929
2 PIK3CA NM_006218.4(PIK3CA):c.3203dup (p.Asn1068fs) DUP Pathogenic
13658 rs587776802 GRCh37: 3:178952146-178952147
GRCh38: 3:179234358-179234359
3 APC NM_000038.6(APC):c.3359G>A (p.Gly1120Glu) SNV Pathogenic
802 rs28933379 GRCh37: 5:112174650-112174650
GRCh38: 5:112838953-112838953
4 MUTYH NM_001048174.2(MUTYH):c.1129C>T (p.Pro377Ser) SNV Pathogenic
5298 rs121908382 GRCh37: 1:45797202-45797202
GRCh38: 1:45331530-45331530
5 MUTYH NM_001048174.2(MUTYH):c.1157A>G (p.Gln386Arg) SNV Pathogenic
5299 rs121908383 GRCh37: 1:45797174-45797174
GRCh38: 1:45331502-45331502
6 KLF6 NM_001300.6(KLF6):c.465C>A (p.Ser155Arg) SNV Pathogenic
7574 rs121909144 GRCh37: 10:3824044-3824044
GRCh38: 10:3781852-3781852
7 ERBB2 NM_004448.4(ERBB2):c.2326G>A (p.Gly776Ser) SNV Pathogenic
13879 rs28933369 GRCh37: 17:37880997-37880997
GRCh38: 17:39724744-39724744
8 IRF1 NM_002198.3(IRF1):c.22A>T (p.Met8Leu) SNV Pathogenic
14720 rs121912469 GRCh37: 5:131825149-131825149
GRCh38: 5:132489457-132489457
9 KRAS NM_004985.5(KRAS):c.34G>A (p.Gly12Ser) SNV Pathogenic
12584 rs121913530 GRCh37: 12:25398285-25398285
GRCh38: 12:25245351-25245351
10 FGFR2 NM_000141.5(FGFR2):c.799T>C (p.Ser267Pro) SNV Pathogenic
13290 rs121918505 GRCh37: 10:123279633-123279633
GRCh38: 10:121520119-121520119
11 FGFR2 NM_000141.5(FGFR2):c.1150G>A (p.Gly384Arg) SNV Pathogenic
478046 rs1554927408 GRCh37: 10:123274768-123274768
GRCh38: 10:121515254-121515254
12 FGFR2 NM_000141.5(FGFR2):c.1124A>G (p.Tyr375Cys) SNV Pathogenic
13277 rs121913478 GRCh37: 10:123274794-123274794
GRCh38: 10:121515280-121515280
13 FGFR2 NM_000141.5(FGFR2):c.1025G>A (p.Cys342Tyr) SNV Pathogenic
13263 rs121918487 GRCh37: 10:123276892-123276892
GRCh38: 10:121517378-121517378
14 PIK3CA NM_006218.4(PIK3CA):c.3139C>T (p.His1047Tyr) SNV Pathogenic
39705 rs121913281 GRCh37: 3:178952084-178952084
GRCh38: 3:179234296-179234296
15 MUTYH NM_001048174.2(MUTYH):c.650G>A (p.Arg217His) SNV Pathogenic
140877 rs140342925 GRCh37: 1:45798117-45798117
GRCh38: 1:45332445-45332445
16 MUTYH NM_001048174.2(MUTYH):c.305-1G>C SNV Pathogenic
234229 rs372267274 GRCh37: 1:45798843-45798843
GRCh38: 1:45333171-45333171
17 MUTYH NM_001048174.2(MUTYH):c.13C>T (p.Arg5Ter) SNV Pathogenic
127845 rs587780088 GRCh37: 1:45800165-45800165
GRCh38: 1:45334493-45334493
18 APC NM_000038.6(APC):c.694C>T (p.Arg232Ter) SNV Pathogenic
42248 rs397515734 GRCh37: 5:112128191-112128191
GRCh38: 5:112792494-112792494
19 APC NM_000038.6(APC):c.1660C>T (p.Arg554Ter) SNV Pathogenic
807 rs137854573 GRCh37: 5:112164586-112164586
GRCh38: 5:112828889-112828889
20 APC NM_000038.6(APC):c.2805C>A (p.Tyr935Ter) SNV Pathogenic
810 rs137854575 GRCh37: 5:112174096-112174096
GRCh38: 5:112838399-112838399
21 FGFR2 NM_000141.5(FGFR2):c.758C>G (p.Pro253Arg) SNV Pathogenic
13273 rs77543610 GRCh37: 10:123279674-123279674
GRCh38: 10:121520160-121520160
22 FGFR2 NM_000141.5(FGFR2):c.755C>G (p.Ser252Trp) SNV Pathogenic
13272 rs79184941 GRCh37: 10:123279677-123279677
GRCh38: 10:121520163-121520163
23 MUTYH NM_001048174.2(MUTYH):c.1103-2A>G SNV Pathogenic
141282 rs587781628 GRCh37: 1:45797230-45797230
GRCh38: 1:45331558-45331558
24 APC NM_000038.6(APC):c.70C>T (p.Arg24Ter) SNV Pathogenic
184702 rs145945630 GRCh37: 5:112090657-112090657
GRCh38: 5:112754960-112754960
25 APC NM_000038.6(APC):c.637C>T (p.Arg213Ter) SNV Pathogenic
140952 rs587781392 GRCh37: 5:112116592-112116592
GRCh38: 5:112780895-112780895
26 APC NM_000038.6(APC):c.646C>T (p.Arg216Ter) SNV Pathogenic
127312 rs62619935 GRCh37: 5:112128143-112128143
GRCh38: 5:112792446-112792446
27 APC NM_000038.6(APC):c.847C>T (p.Arg283Ter) SNV Pathogenic
184999 rs786201856 GRCh37: 5:112151204-112151204
GRCh38: 5:112815507-112815507
28 APC NM_000038.6(APC):c.933+1G>A SNV Pathogenic
233970 rs876660765 GRCh37: 5:112151291-112151291
GRCh38: 5:112815594-112815594
29 FGFR2 NM_000141.5(FGFR2):c.1032G>A (p.Ala344=) SNV Pathogenic
13268 rs121918491 GRCh37: 10:123276885-123276885
GRCh38: 10:121517371-121517371
30 FGFR2 NM_000141.5(FGFR2):c.314A>G (p.Tyr105Cys) SNV Pathogenic
449024 rs1434545235 GRCh37: 10:123325014-123325014
GRCh38: 10:121565500-121565500
31 APC NM_000038.6(APC):c.3199C>T (p.Gln1067Ter) SNV Pathogenic
803 rs137854571 GRCh37: 5:112174490-112174490
GRCh38: 5:112838793-112838793
32 CASP10 NM_032977.4(CASP10):c.440T>C (p.Met147Thr) SNV Pathogenic
7768 rs121909776 GRCh37: 2:202052521-202052521
GRCh38: 2:201187798-201187798
33 KRAS NM_004985.5(KRAS):c.35G>A (p.Gly12Asp) SNV Pathogenic
12582 rs121913529 GRCh37: 12:25398284-25398284
GRCh38: 12:25245350-25245350
34 PIK3CA NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg) SNV Pathogenic
13652 rs121913279 GRCh37: 3:178952085-178952085
GRCh38: 3:179234297-179234297
35 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys) SNV Pathogenic
13655 rs104886003 GRCh37: 3:178936091-178936091
GRCh38: 3:179218303-179218303
36 MUTYH NM_001048174.2(MUTYH):c.1103G>A (p.Gly368Asp) SNV Pathogenic
Pathogenic
5294 rs36053993 GRCh37: 1:45797228-45797228
GRCh38: 1:45331556-45331556
37 MUTYH NM_001048174.2(MUTYH):c.452A>G (p.Tyr151Cys) SNV Pathogenic
Likely Pathogenic
5293 rs34612342 GRCh37: 1:45798475-45798475
GRCh38: 1:45332803-45332803
38 APC NM_000038.6(APC):c.3867T>A (p.Cys1289Ter) SNV Pathogenic
545962 rs1554085355 GRCh37: 5:112175158-112175158
GRCh38: 5:112839461-112839461
39 BRCA2 NM_000059.4(BRCA2):c.8488-1G>A SNV Pathogenic
38164 rs397507404 GRCh37: 13:32945092-32945092
GRCh38: 13:32370955-32370955
40 CDH1 NM_004360.5(CDH1):c.1296C>G (p.Asn432Lys) SNV Likely Pathogenic
186937 rs187862045 GRCh37: 16:68847374-68847374
GRCh38: 16:68813471-68813471
41 MUTYH NM_001048174.2(MUTYH):c.850-2A>G SNV Likely Pathogenic
41766 rs77542170 GRCh37: 1:45797760-45797760
GRCh38: 1:45332088-45332088
42 TP53 NM_000546.6(TP53):c.751A>C (p.Ile251Leu) SNV Likely Pathogenic
182937 rs730882007 GRCh37: 17:7577530-7577530
GRCh38: 17:7674212-7674212
43 CDH1 NM_004360.5(CDH1):c.2494G>A (p.Val832Met) SNV Likely Pathogenic
12246 rs35572355 GRCh37: 16:68867247-68867247
GRCh38: 16:68833344-68833344
44 TP53 NM_000546.6(TP53):c.847C>T (p.Arg283Cys) SNV Likely Pathogenic
127824 rs149633775 GRCh37: 17:7577091-7577091
GRCh38: 17:7673773-7673773
45 APC NM_000038.6(APC):c.1312+3A>G SNV Likely Pathogenic
217924 rs863225311 GRCh37: 5:112155044-112155044
GRCh38: 5:112819347-112819347
46 MUTYH NM_001048174.2(MUTYH):c.1145_1146dup (p.Pro383fs) DUP Likely Pathogenic
417906 rs1553125914 GRCh37: 1:45797184-45797185
GRCh38: 1:45331512-45331513
47 CTNNB1 NM_001904.4(CTNNB1):c.109T>C (p.Ser37Pro) SNV Likely Pathogenic
376234 rs121913228 GRCh37: 3:41266112-41266112
GRCh38: 3:41224621-41224621
48 CTNNB1 NM_001904.4(CTNNB1):c.110C>A (p.Ser37Tyr) SNV Likely Pathogenic
375894 rs121913403 GRCh37: 3:41266113-41266113
GRCh38: 3:41224622-41224622
49 FGFR2 NM_000141.5(FGFR2):c.1013G>A (p.Gly338Glu) SNV Likely Pathogenic
374817 rs1057519044 GRCh37: 10:123276904-123276904
GRCh38: 10:121517390-121517390
50 FANCI NM_001113378.2(FANCI):c.1804C>T (p.Arg602Ter) SNV Likely Pathogenic
929725 rs1432325198 GRCh37: 15:89828432-89828432
GRCh38: 15:89285201-89285201

UniProtKB/Swiss-Prot genetic disease variations for Gastric Cancer:

73 (show all 19)
# Symbol AA change Variation ID SNP ID
1 APC p.Gly817Cys VAR_005035
2 APC p.Ile880Thr VAR_005036 rs1400295986
3 APC p.Asn942Asp VAR_005039
4 APC p.Gly1120Glu VAR_005042 rs28933379
5 APC p.Arg1171His VAR_005043 rs372481703
6 APC p.Phe1197Ser VAR_005045
7 APC p.Ile1259Thr VAR_005046
8 APC p.Gly1312Glu VAR_005050
9 APC p.Val1326Ala VAR_005052
10 CASP10 p.Met147Thr VAR_037428 rs121909776
11 IRF1 p.Met8Leu VAR_065134 rs121912469
12 IRF1 p.Trp11Arg VAR_065135 rs121912470
13 KRAS p.Gly12Val VAR_006840 rs121913529
14 KRAS p.Gly12Asp VAR_016026 rs121913529
15 KRAS p.Gly12Ser VAR_016028 rs121913530
16 KRAS p.Gly13Asp VAR_016029 rs112445441
17 KRAS p.Ala59Thr VAR_016030 rs121913528
18 KRAS p.Lys5Asn VAR_064849 rs104894361
19 MUTYH p.Pro402Ser VAR_026049 rs121908382

Cosmic variations for Gastric Cancer:

8 (show top 50) (show all 46209)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM94780361 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.1159G>A p.A387T 18:25226759-25226759 30
2 COSM131486960 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.1159G>A p.A387T 18:25226759-25226759 30
3 COSM140706619 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.499G>A p.A167T 18:25226759-25226759 30
4 COSM94777296 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.2285G>A p.R762H 18:25225633-25225633 30
5 COSM131495211 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.443G>A p.C148Y 18:25227475-25227475 30
6 COSM140704933 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.1625G>A p.R542H 18:25225633-25225633 30
7 COSM94795709 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.3434T>G p.V1145G 18:25224484-25224484 30
8 COSM94788727 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.443G>A p.C148Y 18:25227475-25227475 30
9 COSM140712668 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.-218G>A p.? 18:25227475-25227475 30
10 COSM131483683 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.2285G>A p.R762H 18:25225633-25225633 30
11 COSM131502188 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.3434T>G p.V1145G 18:25224484-25224484 30
12 COSM140717636 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.2774T>G p.V925G 18:25224484-25224484 30
13 COSM89892679 ZNF384 stomach,NS,carcinoma,adenocarcinoma c.1136G>A p.R379Q 12:6669044-6669044 30
14 COSM99686061 ZNF384 stomach,NS,carcinoma,adenocarcinoma c.1319G>A p.R440Q 12:6669044-6669044 30
15 COSM96892872 ZNF384 stomach,NS,carcinoma,adenocarcinoma c.1319G>A p.R440Q 12:6669044-6669044 30
16 COSM92495186 ZNF384 stomach,NS,carcinoma,adenocarcinoma c.971G>A p.R324Q 12:6669044-6669044 30
17 COSM90523509 ZNF341 stomach,NS,carcinoma,adenocarcinoma c.2512G>A p.A838T 20:33791485-33791485 30
18 COSM98293254 ZNF341 stomach,NS,carcinoma,adenocarcinoma c.2533G>A p.A845T 20:33791485-33791485 30
19 COSM84509305 ZNF276 stomach,NS,carcinoma,adenocarcinoma c.*677T>G p.? 16:89738923-89738923 30
20 COSM102042239 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.5456G>T p.R1819L 16:72794484-72794484 30
21 COSM149288723 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.1081G>A p.G361R 16:72959065-72959065 30
22 COSM149261321 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.1858C>T p.H620Y 16:72958288-72958288 30
23 COSM102020152 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.-23-7323C>T p.? 16:72958288-72958288 30
24 COSM87271088 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.1858C>T p.H620Y 16:72958288-72958288 30
25 COSM87290698 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.795C>A p.D265E 16:72959351-72959351 30
26 COSM87291716 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.4553G>T p.G1518V 16:72798129-72798129 30
27 COSM149332052 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.5929G>C p.G1977R 16:72796753-72796753 30
28 COSM87280547 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.1081G>A p.G361R 16:72959065-72959065 30
29 COSM102040971 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.-23-8386C>A p.? 16:72959351-72959351 30
30 COSM87291652 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.8198G>T p.R2733L 16:72794484-72794484 30
31 COSM87296752 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.5929G>C p.G1977R 16:72796753-72796753 30
32 COSM149318848 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.4553G>T p.G1518V 16:72798129-72798129 30
33 COSM149318790 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.8198G>T p.R2733L 16:72794484-72794484 30
34 COSM102042308 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.1811G>T p.G604V 16:72798129-72798129 30
35 COSM149315912 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.795C>A p.D265E 16:72959351-72959351 30
36 COSM102030210 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.-23-8100G>A p.? 16:72959065-72959065 30
37 COSM102048038 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.3187G>C p.G1063R 16:72796753-72796753 30
38 COSM89893344 YES1 stomach,NS,carcinoma,adenocarcinoma c.350G>A p.R117K 18:751726-751726 30
39 COSM136835352 YES1 stomach,NS,carcinoma,adenocarcinoma c.365G>A p.R122K 18:751726-751726 30
40 COSM152021882 YES1 stomach,NS,carcinoma,adenocarcinoma c.350G>A p.R117K 18:751726-751726 30
41 COSM143039512 YAP1 stomach,NS,carcinoma,adenocarcinoma c.356C>G p.T119S 11:102114178-102114178 30
42 COSM145026456 YAP1 stomach,NS,carcinoma,adenocarcinoma c.356C>G p.T119S 11:102114178-102114178 30
43 COSM85235472 YAP1 stomach,NS,carcinoma,adenocarcinoma c.356C>G p.T119S 11:102114178-102114178 30
44 COSM128450026 YAP1 stomach,NS,carcinoma,adenocarcinoma c.356C>G p.T119S 11:102114178-102114178 30
45 COSM126971185 YAP1 stomach,NS,carcinoma,adenocarcinoma c.-179C>G p.? 11:102114178-102114178 30
46 COSM133271379 YAP1 stomach,NS,carcinoma,adenocarcinoma c.356C>G p.T119S 11:102114178-102114178 30
47 COSM127996054 YAP1 stomach,NS,carcinoma,adenocarcinoma c.356C>G p.T119S 11:102114178-102114178 30
48 COSM90945716 YAP1 stomach,NS,carcinoma,adenocarcinoma c.356C>G p.T119S 11:102114178-102114178 30
49 COSM97252932 XRCC2 stomach,NS,carcinoma,adenocarcinoma c.140A>G p.H47R 7:152649345-152649345 30
50 COSM101975785 XPO1 stomach,NS,carcinoma,adenocarcinoma c.479G>A p.S160N 2:61499824-61499824 30

Copy number variations for Gastric Cancer from CNVD:

6 (show top 50) (show all 694)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13401 1 1 2300000 Gain SLC35E2A Gastric cancer
2 13782 1 1 39600000 Gain LCK Gastric cancer
3 13783 1 1 39600000 Gain MDS2 Gastric cancer
4 13784 1 1 39600000 Gain PAX7 Gastric cancer
5 13785 1 1 39600000 Gain PRDM16 Gastric cancer
6 13786 1 1 39600000 Gain RPL22 Gastric cancer
7 13787 1 1 39600000 Gain SDHB Gastric cancer
8 13988 1 102200000 107200000 Loss AMY1A Gastric cancer
9 13989 1 102200000 107200000 Loss AMY2A Gastric cancer
10 19425 1 150222010 150233338 Amplification S100A10 Gastric cancer
11 22648 1 168031174 168088853 Amplification C1orf112 Gastric cancer
12 22794 1 168899937 168975165 Amplification PRRX1 Gastric cancer
13 24343 1 178867796 179122103 Amplification XPR1 Gastric cancer
14 25997 1 195319997 195382287 Amplification ASPM Gastric cancer
15 26293 1 198787930 198856485 Amplification KIF14 Gastric cancer
16 27965 1 216525252 216577948 Amplification RRP15 Gastric cancer
17 28583 1 223655827 223682407 Amplification LBR Gastric cancer
18 29302 1 2300000 5400000 Gain TP73 Gastric cancer
19 29303 1 2300000 5400000 Gain WRAP73 Gastric cancer
20 29725 1 234780594 234834437 Amplification HEATR1 Gastric cancer
21 30108 1 240078158 240119671 Amplification EXO1 Gastric cancer
22 30593 1 244770489 244796186 Amplification TFB2M Gastric cancer
23 37702 1 938709 939782 Copy number ISG15 Gastric cancer
24 37787 1 94700000 99700000 Loss DPYD Gastric cancer
25 38140 10 1 135006516 Loss Gastric cancer
26 40043 10 123336181 123337713 Amplification FGFR2 Gastric cancer
27 40401 10 127500000 130600000 Gain Gastric cancer
28 41839 10 24600000 135534747 Loss Gastric cancer
29 45622 10 73000000 81800000 Amplification PSAP Gastric cancer
30 48318 11 1 135006516 Gain Gastric cancer
31 49710 11 110400000 130800000 Gain Gastric cancer
32 49997 11 112500000 130800000 Gain Gastric cancer
33 53360 11 2800000 10700000 Gain CDKN1C Gastric cancer
34 53361 8 145646122 145661839 Gain ZFTRAF1 Gastric cancer
35 53362 8 145669924 145672526 Gain FOXH1 Gastric cancer
36 53363 11 2800000 10700000 Gain KCNQ1 Gastric cancer
37 53364 11 2800000 10700000 Gain KCNQ1DN Gastric cancer
38 53365 8 145662545 145670307 Gain KIFC2 Gastric cancer
39 53366 11 2800000 10700000 Gain SLC22A18 Gastric cancer
40 53367 11 2800000 10700000 Gain SLC22A18AS Gastric cancer
41 54234 11 40200000 42900000 Amplification LRRC4C Gastric cancer
42 56156 11 57265297 57267459 Copy number SELENOH Gastric cancer
43 56517 11 59900000 61700000 Gain PGA5 Gastric cancer
44 58503 11 68100000 70400000 Amplification CCND1 Gastric cancer
45 58504 11 68100000 70400000 Amplification FGF3 Gastric cancer
46 58651 11 69161019 69306967 Amplification CCND1 Gastric cancer
47 58653 11 69161019 69306967 Amplification FGF19 Gastric cancer
48 58655 11 69161019 69306967 Amplification FGF4 Gastric cancer
49 58657 11 69161019 69306967 Amplification LTO1 Gastric cancer
50 59248 11 73719009 73787150 Amplification PGM2L1 Gastric cancer

Expression for Gastric Cancer

Search GEO for disease gene expression data for Gastric Cancer.

Pathways for Gastric Cancer

Pathways related to Gastric Cancer according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.3 PIK3CA KRAS IRF1 IL1B FGFR2 ERBB2
2
Show member pathways
12.49 PIK3CA KRAS IRF1 IL1B FGFR2
3
Show member pathways
12.42 PIK3CA KRAS FGFR2 ERBB2 BRCA2 APC
4
Show member pathways
12.33 CASP10 ERBB2 KRAS PIK3CA
5
Show member pathways
12.27 PIK3CA IRF1 IL1RN IL1B
6
Show member pathways
12.22 PIK3CA KRAS FGFR2 ERBB2 APC
7
Show member pathways
12.07 PIK3CA KRAS FGFR2 ERBB2
8
Show member pathways
12.06 PIK3CA KRAS FGFR2 ERBB2 BRCA2 APC
9 11.97 PIK3CA KRAS FGFR2 APC
10
Show member pathways
11.95 FGFR2 MIR15B MIR21 PIK3CA
11 11.9 KRAS FGFR2 ERBB2 APC
12
Show member pathways
11.85 PIK3CA KRAS IL1B FGFR2 ERBB2 CASP10
13 11.68 PIK3CA KRAS ERBB2 APC
14
Show member pathways
11.64 PIK3CA KRAS CASP10
15
Show member pathways
11.63 MIR221 MIR145 MIR143
16 11.49 MIR21 MIR145 IRF1
17 11.42 ERBB2 FGFR2 KRAS PIK3CA
18 11.1 PIK3CA IRF1 IL1B
19 11.03 KRAS ERBB2 APC
20 10.99 MIR27A MIR25 MIR221 MIR21 MIR15B MIR145

GO Terms for Gastric Cancer

Cellular components related to Gastric Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RISC complex GO:0016442 9.53 MIR27A MIR25 MIR221 MIR215 MIR21 MIR15B
2 extracellular vesicle GO:1903561 9.35 MIR27A MIR221 MIR215 MIR21 MIR15B

Biological processes related to Gastric Cancer according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell population proliferation GO:0008285 10.15 MIR221 MIR21 MIR15B IRF1 IL1B APC
2 miRNA-mediated gene silencing GO:0035195 10.13 MIR27A MIR25 MIR221 MIR215 MIR21 MIR15B
3 positive regulation of apoptotic process GO:0043065 10.04 MIR27A MIR221 MIR21 MIR15B APC
4 positive regulation of protein kinase B signaling GO:0051897 9.91 PIK3CA MIR221 MIR21 MIR143
5 positive regulation of epithelial to mesenchymal transition GO:0010718 9.86 MIR221 MIR21 IL1B
6 negative regulation of angiogenesis GO:0016525 9.78 MIR21 MIR15B MIR145 MIR143
7 negative regulation of regulatory T cell differentiation GO:0045590 9.72 MIR21 IRF1
8 positive regulation of vascular associated smooth muscle cell proliferation GO:1904707 9.71 MIR27A MIR221 MIR21
9 regulation of ERK1 and ERK2 cascade GO:0070372 9.7 MIR145 IL1B FGFR2 ERBB2
10 negative regulation of vascular associated smooth muscle cell differentiation GO:1905064 9.58 MIR221 MIR15B
11 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.58 MIR221 MIR21 MIR143
12 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.56 MIR27A MIR21 IL1RN
13 aorta smooth muscle tissue morphogenesis GO:0060414 9.52 MIR145 MIR143
14 regulation of phenotypic switching GO:1900239 9.46 MIR143 MIR145
15 positive regulation of cellular response to hypoxia GO:1900039 9.43 MIR21 MIR145
16 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.37 MIR145 MIR143
17 miRNA-mediated gene silencing by inhibition of translation GO:0035278 9.35 MIR27A MIR221 MIR21 MIR15B MIR145
18 negative regulation of interleukin-21 production GO:0032705 8.8 MIR221 MIR215 MIR21

Molecular functions related to Gastric Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.35 MIR27A MIR21 MIR15B MIR145 MIR143
2 mRNA base-pairing translational repressor activity GO:1903231 9.23 MIR27A MIR25 MIR221 MIR215 MIR21 MIR15B

Sources for Gastric Cancer

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....